How to Spot Patent Portfolio Debt Before It Becomes Expensive

Introduction : Corporate finance teams have long used the term “technical debt” to describe the deferred cost of quick, expedient engineering choices. Patent portfolios accumulate a close cousin of this liability. A patent filed opportunistically, drafted around a product that was later discontinued, or maintained in a jurisdiction with no commercial footprint, does not announce its own uselessness. It simply stays in the register, generating renewal fees, legal fees, until such time that a licensing transaction, an acquisition or even a simple annuity evaluation brings to the attention of the company its true value. This is a liability of the patent portfolio, i.e. the total cost incurred due to ineffective, redundant and/or inappropriate filings which have never been weeded out.

The issue is not limited to one particular jurisdiction, but the UK and the US provide great examples since they both have the same structure of payments: they are intended to enable such reflection. The US USPTO is collecting maintenance fees on a recurrent basis according to 35 U.S.C. § 41(b), and the fee amount is going to be significantly increased starting from 19 January 2025 while the UK IPO and the EPO are implementing their annuity scheme according to the Patents Act 1977 and the EPC.

Legal Provisions

A. United States : Under 35 U.S.C. § 41(b), the proprietor of a US Maintenance fees must be paid throughout the term of the application, requiring payment at 3.5 years, 7.5 years, and 11.5 years after the date of grant, otherwise the patent will lapse (with the possibility of extending by 6 months with additional surcharge). Starting from 19 January 2025, the USPTO has increased the fees due at most stages of the patent process. Maintenance costs have grown by about 7.5% for every step, resulting in $8,280 being the amount paid by large companies at 11.5 years, while filing, search, and examination fees increased separately by 2.5%. The USPTO has implemented new fees of 2,700 and 4,000 USD for continuation, continuation-in-part, divisional, or PCT bypass applications submitted six or nine or more years after the date of claiming benefit.

The second source of risk is the doctrine of prosecution laches, which is a common law doctrine relevant for ensuring enforcement of the patent, as it can be claimed, if an applicant has been delaying prosecution unfairly for an unreasonably long time and this has caused harm to the accused infringer. This legal concept is important for patent portfolio lending, as it interferes with the practice of filing a lot of unresolved continuation applications, which does not improve the concept commercial aspect but is used.

Separately, 35 U.S.C. § 101 and the two-step framework it has generated for assessing patent-eligible subject matter remain a live source of latent invalidity risk for software and business-method claims

drafted before, or without regard to, that framework. Weak claims of this kind often survive on the register for years, appearing as assets until they are tested.

B. United Kingdom and Europe

According to Section 25 of the Patents Act 1977, an annual renewal fee is necessary for a UK patent to remain in effect; it also states that the patent becomes invalid if this fee is not paid during the required time period (with a grace of six more months available at an additional cost). Under Section 28, a lapsed patent may be restored, but the comptroller must be convinced that the failure to pay the renewal is due to an “accidental” event.

European patents validated in the UK, and Unitary Patents before the Unified Patent Court, are subject to their own escalating annuity schedules administered by the EPO and, for Unitary Patents, a single renewal fee payable to the EPO in lieu of national renewals. Because these annuities rise steeply with the age of the patent, precisely the years in which a weak or commercially orphaned filing is most expensive to keep are also the years in which its uselessness is most likely to have become apparent.

Legal Analysis

A. What Portfolio Debt Actually Looks Like

Patent debt is rarely a single defective filing; it is a pattern. Three recurring symptoms are worth isolating. First, claim-to-product misalignment: patents whose claims no longer map to any product, platform, or roadmap item the business actually sells or plans to sell. Second, jurisdictional sprawl: national filings maintained in countries where the applicant has no manufacturing, sales, or credible enforcement interest, often the by-product of a default “file everywhere” instruction given years earlier without a corresponding budget discipline. Third, duplicative or near-identical claim sets pursued across multiple continuations or divisional of the same family, generated for optionality rather than to capture a distinct inventive contribution. None of these symptoms is visible from a docketing system that tracks deadlines and counts; each requires a substantive, claim-level review.

B. The Maintenance Fee Cliff

Empirical data on US maintenance fee compliance illustrates how debt compounds if left unaddressed. The maintenance fees data collected by USPTO clearly indicates that the number of patent holders paying maintenance fees has gone down from around 52% from 2012-2013 to around 40% now, which in other words means nearly 60% of patentholders abandon their patent before its full term instead of paying fees that have gone up. The increase in fees in January 2025 makes this calculation even more urgent: portfolios which were worth keeping under the previous fee schedule might not be worth keeping any more, and the company that hasn’t checked its patents according to the new fees might end up having too many patents abandoned without effort and without any planning.an expensive surprise or an unplanned wave of abandonments driven by cost rather than strategy.

C. Duplicative Filings and the Doctrine of Prosecution Laches

The ruling made by the Federal Circuit in In re Bogese shows that excessive continuation practices not only incurs costs; it also can lead to the loss of the right to obtain patents. In the case, the patent applicant submitted twelve applications during the eight years and did not really push forward the prosecution process, which the Federal Circuit regarded as unreasonable and unjustified delay, which is enough to lose the patent rights under the practice of prosecution laches. Following cases, like Personalized Media Communications, LLC v. Apple, Inc. and Sonos, Inc. v. Google LLC, utilized the same principles to declare that issued patents are unenforceable, based on the long patenting chain practices initiated during GATT era that bears some connection to the products of rivals released at a later date. The lesson for portfolio management is that a chain of continuations kept alive indefinitely “just in case” does not merely waste prosecution budget; it can convert into a documented pattern that a future defendant uses to invalidate the very patents the business was trying to preserve.

D. Weak Claims, the Alice Overhang, and Shifting PTAB Dynamics

For software and business-method claims, the Supreme Court's decision in Alice Corp. v. CLS Bank International remains the principal doctrinal source of latent weakness. Alice held that merely implementing an abstract idea on a generic computer does not transform that idea into patent-eligible subject matter, and the decision continues to function as the most frequently invoked tool for invalidating claims of this kind. A portfolio built up before, or without regard to, the Alice framework may contain a substantial proportion of claims that would not survive a serious eligibility challenge, even though nothing on the face of the patent register discloses this.

It is tempting to assume that declining institution rates at the Patent Trial and Appeal Board reduce this risk. Recent USPTO figures show the overall inter partes review institution rate falling from around 65% in October 2024 to around 37% by February 2026, reflecting a shift toward discretionary denial of petitions. That shift changes where weak claims are tested, more often in district court litigation or transactional diligence rather than at the PTAB, but it does not repair the underlying claims. A lower institution rate should not be read by portfolio owners as validation of claim quality; it is a change in forum dynamics, not a cure for eligibility or prior-art weaknesses that remain latent in the portfolio.

E. The UK Asymmetry: Pruning Is a One-Way Door

UK law adds a distinctive discipline to portfolio pruning that US practice does not impose in quite the same way. In Atlas Powder Co's Patent, the Patents Court confirmed that section 28 restoration exists to relieve a proprietor from an unintentional failure to pay a renewal fee, not from a deliberate decision not to pay it, even where that decision was reasonable on the facts available at the time and later turns out to have been based on incomplete information. In other words, once a business consciously decides to let a UK or European patent lapse as part of a portfolio-pruning exercise, that decision cannot later be reversed through restoration if new information suggests the asset was more valuable than assumed. This makes the initial audit far more consequential in the UK/European context than in the US, where a lapsed patent facing a similar reassessment has, at most, the same discretionary abandonment calculus rather than a legal bar dependent on whether the original non-payment was a deliberate choice.

Case Laws

In re Bogese, 303 F.3d 1362 (Fed. Cir. 2002): The Federal Circuit held that filing twelve continuation applications over eight years without substantively advancing prosecution forfeited the applicant's patent rights under the doctrine of prosecution laches, the founding modern authority on how duplicative continuation practice converts into unenforceability.

Personalized Media Communications, LLC v. Apple, Inc., No. 2:15-cv-01366 (E.D. Tex. 2021): A patent issued from a continuation chain filed during the 1995 “GATT bubble” was held unenforceable for prosecution laches after an eight-to-sixteen-year delay in presenting the asserted claims, vacating a jury verdict of approximately $300 million.

Sonos, Inc. v. Google LLC, No. C 20-06754 (N.D. Cal. 2023): Two patents issued from a continuation chain claiming priority to a filing thirteen years earlier were held unenforceable for prosecution laches, illustrating that even portfolios built through ordinary continuation practice can be exposed if the chain is not periodically resolved.

Alice Corp. Pty. Ltd. v. CLS Bank International, 573 U.S. 208 (2014): The Supreme Court ruled that merely putting an abstract idea into a generic computer doesn't make it patent eligible under 35 U.S.C. § 101, setting the precedent that serves as a blueprint for giving invalid patents in the fields of software and business methods the attention they deserve.

Atlas Powder Co's Patent [1995] RPC 357 (Patents Court, UK): The court has ruled that section 28 restoration is not applicable when the patentee takes an explicit decision not to pay a renewal fee, regardless of the rationality of that decision at the point of time, thereby making it clear that the decisions on pruning the portfolio are irrevocable according to UK law.

Practical Implications

For businesses and their advisors, patent debt surfaces most visibly at three moments: a licensing or M&A due diligence exercise, an annual renewal budget cycle, and a litigation threat assessment. Each of these moments rewards preparation over reaction. A practical audit should map every claim in the portfolio to a current product, roadmap item, or credible licensing target, rather than merely tracking filing counts; it should tier assets (for example, core, defensive, and candidate-for-abandonment) so that renewal budget is allocated deliberately rather than by default; and it should flag any continuation family that has been kept open without a clear, documented commercial or legal rationale, given the prosecution laches exposure illustrated above.

On the cost side, the January 2025 USPTO fee schedule means that renewal budgeting done on historic figures will understate true cost, particularly for portfolios with long continuation chains now subject to the new $2,700 and $4,000 surcharges. On the UK and European side, because a decision not to renew is effectively irreversible once made, any pruning exercise should be preceded by a genuine commercial review, including checks against competitor activity and any pending licensing conversations, and the reasoning for each abandonment decision should be documented contemporaneously. This creates a defensible record if the decision is ever scrutinised, and it also protects against the opposite risk, that of restoring a patent it turns out cannot be restored because the earlier lapse was a conscious choice rather than an oversight.

Finally, businesses should treat a falling PTAB institution rate as a change in venue risk rather than as an improvement in portfolio quality. Weak claims that are less likely to face an early, cost-effective PTAB challenge remain equally vulnerable in district court litigation, in freedom-to-operate opinions relied on by counterparties, and in the valuation models used in transactions, all contexts in which the cost of an undetected weakness is considerably higher than the cost of a timely internal audit.

Conclusion

Patent portfolio debt accumulates through inattention rather than through any single decision, and both UK and US law provide reliable, recurring trigger points, the maintenance fee schedule, the renewal annuity, and the continuation deadline, at which that debt can be identified before it compounds further. The case law canvassed above shows that the cost of ignoring these triggers is not confined to wasted fees: duplicative continuation practice can forfeit patent rights entirely under the doctrine of prosecution laches, and weak claims drafted without regard to the Alice framework remain vulnerable regardless of short-term shifts in PTAB institution rates. The UK's restoration regime adds a further discipline, since a deliberate decision to let a patent lapse cannot later be undone. Read together, these provisions counsel the same practical response: periodic, claim-level portfolio audits, tied to actual commercial use and documented decision-making, are considerably cheaper than discovering patent debt for the first time during a renewal deadline, a licensing negotiation, or a dispute.

Author :- Dhriti Vyas, in case of any query, contact us at Global Patent Filing or write back us via email at support@globalpatentfiling.com.

References (Endnotes)

1. 35 U.S.C. § 41(b) (United States).
2. 35 U.S.C. § 101 (United States).
3. Patents Act 1977, s. 25 (United Kingdom).
4. Patents Act 1977, s. 28 (United Kingdom).
5. In re Bogese, 303 F.3d 1362 (Fed. Cir. 2002) (United States).
6. Personalized Media Communications, LLC v. Apple, Inc., No. 2:15-CV-01366-JRG (E.D. Tex. Aug. 5, 2021) (United States).
7. Sonos, Inc. v. Google LLC, No. C 20-06754 WHA (N.D. Cal. Oct. 6, 2023) (United States).
8. Alice Corp. Pty. Ltd. v. CLS Bank International, 573 U.S. 208 (2014) (United States).
9. Atlas Powder Co's Patent [1995] RPC 357 (Patents Court) (United Kingdom).
10. United States Patent and Trademark Office, USPTO Fee Schedule, effective 19 January 2025.
11. Dickinson Wright, '2025 Patent Filing Costs Rise: USPTO Fee Update and Response Strategies' (2025).
12. Patently-O, 'Are Rising Maintenance Fees Shortening the Effective Patent Term?' (March 2026).
13. IPWatchdog, 'USPTO Stats Show IPR Institution Rate Has Plummeted by 43%' (April 2026).
14. Duane Morris LLP, 'Paying for Your Delay: Application of Prosecution Laches Can Render Issued Patents Unenforceable' (August 2021).